Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 21:00:00 20/05/2026 BST			5-day change	1st Jan Change
298.48 ^USD	+1.42%		+2.40%	-24.94%

05-13	Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10:40 AM
05-12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI

Transcript : Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025

Published on 05/01/2025 at 01:00 pm BST - Modified on 07/09/2025 at 09:52 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. [Operator Instructions] this call is

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

05-13	Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10:40 AM
05-12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI
05-01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
04-30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Alnylam Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
04-30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
04-30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI
03-24	Alnylam Pharmaceuticals, Inc. - Special Call
03-24	Alnylam Pharmaceuticals, Inc. Advances ATTR-CM Care with Strategic Collaboration and AI-Enabled Pathways	CI
03-24	Alnylam Pharmaceuticals, Viz.ai Collaborate on AI-Enabled Detection of Transthyretin Amyloidosis	MT
03-05	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI